Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5369394 | 0.90 | CA2 (0.51) | KDM1APTGS2CA12ABL1CA1 | |
| Hydrochloric Acid SCHEMBL5372894 | 0.89 | ABL1 (0.39) | KDM1APTGS2CA12ABL1CA1 | |
| Hydrochloric Acid SCHEMBL5381404 | 0.88 | SMN1; SMN2 (0.41) | KDM1ACA12ABL1CA1CA2 | |
| SCHEMBL5367582 | 0.83 | KDM1A (0.44) | KDM1A | |
| SCHEMBL27695119 | 0.83 | ABCG2 (0.47) | KDM1A | |
| Hydrochloric Acid SCHEMBL5362034 | 0.82 | KDM1A (0.45) | KDM1A | |
| Hydrochloric Acid SCHEMBL5445815 | 0.81 | MEN1 (0.49) | KDM1A | |
| Hydrochloric Acid SCHEMBL5367305 | 0.80 | CA2 (0.52) | KDM1APTGS2CA12ABL1CA1 | |
| SCHEMBL27715058 | 0.80 | CHRNA7 (0.47) | ABL1 | |
| SCHEMBL27715036 | 0.80 | TNF (0.43) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101107250-A | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS INC (US) | 2008-01-16 | — | — | CN | claimed |
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | claimed |
| CN-101107250-A | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS INC (US) | 2008-01-16 | — | — | CN | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | KDM1A 2829/4885PTGS2 334/4885CA12 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.